A Phase III Study of Docetaxel plus S-1 versus S-1 Alone in the Treatment of Curatively Resected Stage III Gastric Cancer - JACCRO GC-07 (START-2)

Japan Clinical Cancer Reseach Organization (JACCRO)0 个研究点目标入组 1,100 人开始时间: 2013年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Active double cancer (except focal cancer in adenoma of colorectal cancer and carcinoma in situ of cervical cancer) and/or past history of other cancer. 2. Patients with severe postoperative complication (severe postoperative infections, anastomotic leakage, gastrointestinal bleeding). 3. Patients with severe complication (intestinal paralysis, intestinal obstruction, interstitial pneumonitis, pulmonary fibrosis, severe diabetes, uncontrolled hypertension, heart failure, renal failure, liver cirrhosis, liver failure, etc.). 4. Patient with active infectious desease. 5. Patient with positive HBs antigen or positive HCV antibody. 6. Definite contraindications for the use of corticosteroids. 7. History of hypersensitivity to fluoropyrimidines, docetaxel, or medications formulated with polysorbate 80, other severe drug induced allergy or . 8. History of allergy of both iodine and gadolinium. 9. Patient is taking flucytosine. 10. Pregnancy or lactation women, women with suspected pregnancy or men with willing to get pregnant. 11. Patient with psychosis or psychotic symptoms and judged to be difficult to determine participating clinical trial. 12. Any subject judged by the investigator to be unfit for any reason to participate in the study.

发起方

Japan Clinical Cancer Reseach Organization (JACCRO)